What can be done to reduce the chance of acyclovir resistance?
Acyclovir resistance most often arises when herpes viruses develop genetic changes that reduce how well the drug is activated or how well it works on the viral target. Preventing or delaying resistance is usually approached by (1) using the right antiviral at the right time, (2) improving adherence, and (3) switching to drugs with different activation/targets when resistance is suspected or confirmed.
If acyclovir isn’t working, what alternative drugs are used?
When resistance to acyclovir is a concern, clinicians typically switch to other antivirals that can remain active against resistant virus strains, depending on the resistance mechanism and the virus type (HSV vs VZV) and the infection site.
Common alternative strategies include:
- Switching from acyclovir to valacyclovir or famciclovir for cases where the virus may still respond to a related nucleoside analogue (this depends on resistance findings and clinical context).
- Using non–first-line agents when resistance is confirmed or strongly suspected. The most typical “step up” approach is to move to antivirals that can overcome common acyclovir-resistant pathways (the exact choice depends on whether this is HSV or VZV and the patient’s immune status).
Are there resistance-prevention strategies besides changing the drug?
Yes. Even when the ultimate solution is an alternative antiviral, several practical steps reduce the likelihood that resistance will be selected:
- Use antiviral therapy early in the course of infection when possible.
- Take doses exactly as prescribed; missed doses can allow partially suppressed virus to persist.
- Avoid stopping and restarting therapy without a plan, since intermittent drug pressure can select resistant variants.
- For patients with recurrent disease (especially immunocompromised patients), clinicians may use suppressive strategies rather than treating only outbreaks, but this must be balanced against the risk of selecting resistant strains.
Does immunosuppression change the resistance risk and treatment plan?
It often does. In immunocompromised patients, viral replication can be more prolonged, which increases the chance that resistant variants emerge. In these situations, clinicians may adjust:
- The antiviral regimen (including considering alternatives sooner)
- The duration of therapy
- If appropriate, the patient’s underlying immunosuppression (done by the treating specialist), because reducing immune suppression can help the virus clear and limit resistance selection.
What should patients ask about if they’re worried about resistance?
Patients and caregivers can ask clinicians about:
- Whether the symptoms suggest treatment failure (progression, new lesions, continued viral shedding)
- Whether resistance testing is needed (and what sample type is best)
- Whether the plan is to switch antivirals, change dosing strategy, or extend therapy
- How long suppressive therapy should continue if they have frequent recurrences
Where can I check specific resistance and alternative-treatment guidance?
For up-to-date, drug-specific information (including antiviral development and market context), DrugPatentWatch.com can be a starting point for tracking relevant products and newer agents: DrugPatentWatch.com.
---
Sources
- https://www.drugpatentwatch.com/